Journal Club

Schizophrenia Neurotransmission and Receptors – To Dopamine and Beyond

Launch Date
10/10/2023
Credit Amount
0.5
Credit Expires
10/10/2024
This activity is part of a series

Faculty

Anissa Abi-Dargham, MD
Professor and Chair, Department of Psychiatry and Behavioral Health
Lourie Endowed Chair in Psychiatry
SUNY Distinguished Professor
Director, Multi-Modal Translational Imaging Lab
Associate Dean and Associate Vice President, Clinical and Translational Science
Stony Brook University
New York, NY
Anissa Abi-Dargham, MD

Anissa Abi-Dargham, MD, is a State University of New York (SUNY) Distinguished Professor of Psychiatry and Radiology, the Lourie Endowed Chair in Psychiatry, Chair of the Department of Psychiatry and Behavioral Health, and Associate Dean for Clinical and Translational Science at Stony Brook University Renaissance School of Medicine. Dr. Abi-Dargham is a member of the National Academy of Medicine and a Special Lecturer at Columbia University in New York, where she spent the last twenty-two years of her career prior to her move to Stony Brook University in 2016. She is Director of the Multi Modal Translational Imaging (MMTI) Lab and oversees a multidisciplinary team with expertise in multiple neuroimaging modalities used in tandem to address important questions about the brain mechanisms of schizophrenia. She is an internationally recognized leader in the use of molecular imaging of the human brain to study schizophrenia and its comorbidity with addiction.

Dr. Abi-Dargham’s research focuses on molecular markers and their functional significance as measured with multi-modal imaging approaches in psychiatric disorders. She has received funding from the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Alliance for Research on Schizophrenia and Depression (NARSAD), Lilly, Bristol Meyers Squibb (BMS), GlaxoSmithKline (GSK), Forest, and Pierre-Fabre. She is Associate Editor for Neuropsychopharmacology, Deputy Editor for Biological Psychiatry, Past President of the Brain Imaging Council for the Society of Nuclear Medicine (SNM), and Past President of the American College of Neuropsychopharmacology (ACNP). She also helped to validate neuromelanin-sensitive MRI as a biomarker of dopamine function.  Dr. Abi-Dargham has had many collaborations with preclinical scientists to design translational studies that attempt to inform human studies with basic research findings and vice versa.

Explore By Section
Statement of Need Learning Objective Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Recent novel therapies in the treatment of schizophrenia have emerged, going beyond the classic dopamine-blocking mechanisms of action (MOA). Health care professionals (HCPs) may be unaware of the many choices of treatment options based on the different neurotransmitter receptors that are targeted, including serotonergic, glutamatergic, and muscarinic as well as dopaminergic receptors. Understanding the mechanisms behind novel treatments can help HCPs choose the best options and tailor treatment to the specific needs of the patients.

In the first installment of this three-part Journal Club series, Schizophrenia Neurotransmission and Receptors – To Dopamine and Beyond, expert faculty will present the latest information on emerging therapies for schizophrenia, their MOAs and ways to utilize them in the treatment of schizophrenia.

Learning Objective

Evaluate the latest evidence on the neurotransmitters involved in the pathophysiology of schizophrenia.

Financial Support

Supported in whole or in part by an educational grant from Sunovion and Otsuka.

Target Audience

Psychiatrists, nurse practitioners (NPs), physician associates (PAs), psychiatric nurses, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-104-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Abi-Dargham reports the following financial relationships:

Consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; and Sunovion Pharmaceuticals Inc.

Stock Shareholder (directly purchased): Terran Biosciences and System1 Biosciences, Inc.

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

JC-025-101023-90

Schizophrenia Neurotransmission and Receptors – To Dopamine and Beyond
Event Date: 10/10/2023
Register

Activities in the Series

Neuropsychiatric
11/07/2023

Targeting Domains of Schizophrenia with Individualized Therapy

0.5
Register Learn More
Neuropsychiatric
10/23/2023

TAAR1: More Than Just Another Receptor in Schizophrenia

0.5
Register Learn More